Press releases
- Press releases
- Browse
Press releases
The outcome of Helsinn's participation at the 6th annual EULAR 2005 Congress - Vienna, 8-11 June, 2005 More
Active Biotech Advances 57-57 Project With Commencement of Phase I Clinical Trial in patients More
Galapagos NV and ASINEX Ltd announce that they have initiated an integrated drug discovery collaboration in bone and joint diseases. The collaboration will result in a set of optimized leads for Galapagos' validated bone and joint disease drug target More
NIMESULIDE and OXAPROZIN at the EULAR 2005 Congress Vienna, 8-11 June More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2010 - 40 pages - $500
Mar 2011 - 16 pages - $250
Dec 2010 - 84 pages - $500
Jun 2006 - 378 pages - $2,495
Mar 2011 - 34 pages - $1,000
Nov 2011 - 7 pages - $3,835
Apr 2009 - 450 pages - $3,490
Oct 2010 - 169 pages - $3,500
Oct 2011 - 134 pages - $500
Mar 2011 - 82 pages - $500
Your selection
Browse By
- Industry sector
- Academic/Research
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Non-profit org./Government
- Pharmaceutical
- Research tools
- Service
- Therapeutic target
- Arthritis (non-specific)
- Bone fractures
- Bone repair/regeneration
- Osteoarthritis
- Osteopetrosis
- Osteoporosis
- Paget's disease
- Rheumatic disorders (other)
- Rheumatoid arthritis
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us